Biotech Startups

Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers. Its products are in development and designed to integrate with existing fertilizer and biological input programs in modern agriculture.

5 investors

Portola develops research and investigates new targets, modalities, and technologies to address rare disease challenges for patients and their families.

5 investors

Potato builds software that connects scientific research intent to laboratory execution, enabling research teams to accelerate the translation from experimental design to hands-on lab work. The platform is designed for biotech and pharmaceutical research organizations seeking to reduce manual coordination and constraints in the experimental workflow.

5 investors

PredxBio develops tissue analysis software that uses spatial multi-omics data to identify biomarkers and inform drug development decisions. The platform helps pharmaceutical and biotech companies move from exploratory tissue analysis to clinical development with explainable insights about cell states, microenvironments, and therapeutic response patterns.

5 investors

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.

5 investors

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R. Liu's lab at the Broad Institute of MIT and Harvard. The company aims to treat a broad range of genetic diseases.

5 investors

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.

5 investors

Project Eaden develops plant-based meat products using advanced food science techniques, targeting consumers who want sustainable protein alternatives without compromising on taste. The company combines culinary expertise with scientific innovation to create meat alternatives optimized for flavor and environmental impact.

5 investors

Projectus builds empathy-first AI grounded in behavioral science that decodes human emotions and behaviors to deliver actionable insights. It serves pharma, biotech, and commercial teams.

5 investors

Promaxo develops a compact, office-based MRI system designed for point-of-care use, with applications including image-guided prostate interventions. The company operates in the medical imaging and medical device sector.

5 investors

Protealis breeds legume crops such as soybeans and yellow peas and develops proprietary seed coatings with nitrogen-fixing bacteria adapted to the European climate. It supplies seeds and germplasm to European farmers to increase local plant-protein production for meat and dairy alternatives.

5 investors

PuraCath Medical develops disinfection technology for catheter connections designed to reduce infection risk in healthcare settings. The company targets healthcare providers and patients who use catheters.

5 investors

Q.bio provides quantitative biology assessments and longitudinal health monitoring for preventive care, offering comprehensive measurable exams at the scale of premium care providers.

5 investors

Qkine manufactures and supplies high-purity growth factors and cytokines for research and therapeutic applications, serving life sciences researchers and cell therapy developers. The company combines computational and experimental capabilities to produce complex protein-based tools for structural analysis and cell culture research.

5 investors

Quorum Bio develops genetic engineering tools for precision fermentation, enabling the production of complex natural products using engineered non-model microbes. The company targets the food, beverage, wellness, and agriculture industries with nature-based ingredients and biocontrols to replace synthetic chemicals.

5 investors

Rainbow Crops applies AI, genome engineering, and field validation to help seed and breeding companies develop crops with complex traits such as yield stability and drought, heat, and disease resilience. A spin-out of the VIB–UGent ecosystem, it works through collaborative R&D partnerships with seed and breeding companies in agriculture.

5 investors

Reach Industries builds a visual intelligence layer for science, combining AI, software, and hardware to support work in the life sciences. The company develops intelligent systems intended to augment human tasks such as research and problem-solving.

5 investors

Potato builds software that bridges scientific research and laboratory execution, enabling research teams to move from hypothesis to experiment to learning faster by automating the manual processes between scientific intent and real-world lab work.

5 investors

RegCell Biosciences is a biotechnology company developing regenerative cell therapies, leveraging expertise in cell and gene therapy, manufacturing, and immunology to advance therapeutic treatments.

5 investors

Reshape provides an AI-driven operating system that automates microbiology data capture and analysis for research laboratories. The platform structures experimental results and surfaces insights to help lab teams accelerate research and product development.

5 investors

Reverb Therapeutics develops immunotherapies built on its Amplify•R platform, which modulates the body's natural immune system using targeted molecules such as IL-15-directed compounds. Its pipeline addresses cancer, autoimmune disease, and cell therapy support, with lead candidate AMP01 advancing toward clinical trials.

5 investors

NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation. The company operates in the biotechnology and drug development sector.

5 investors

Rezo maps disease networks to find insights into disease biology for drug discovery. The company operates in the biotechnology and drug discovery space.

5 investors

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway. The company's lead product, IMCIVREE (setmelanotide), is FDA-approved to treat severe obesity caused by genetic impairments in the hypothalamus.

5 investors